ArticleBMC cancer2026
Co-targeting cystathionine gamma-lyase and mTOR: a promising therapeutic strategy in clear cell ovarian cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Clear cell ovarian carcinoma (CCOC) is a rare, aggressive ovarian cancer subtype, comprising approximately 12% of epithelial ovarian carcinoma (EOC) cases in Western countries yet associated with the worst prognoses due to its chemoresistance. Most CCOCs harbor activating PIK3CA mutations that drive PI3K/AKT/mTOR signaling and HIF1α expression. Despite their clinical success in some cancers, mTOR inhibitors have shown limited efficacy in CCOC, even though this pathway is highly active. Consequently, CCOC continues to be managed like other epithelial ovarian cancers. We recently uncovered cystathionine γ-lyase (CTH), a key enzyme in the transsulfuration pathway, as a metabolic vulnerability in CCOC, supporting HIF1α expression, survival and metastasis. This study aims to address whether simultaneously targeting CTH and mTOR could enhance therapeutic outcomes beyond those achieved by mTOR inhibition alone.CCOC lines were engineered with CTH knockout (KO) or treated with the CTH inhibitor Aviglycine hydrochloride (AVG; ABG-3168); mTOR was blocked with everolimus, a clinical stage mTOR inhibitor. Single and combined treatments were tested in two-dimensional cultures and three-dimensional spheroids under normoxia (21% O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.